For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Read the latest publications using FirePlex® technology.
Researchers around the globe are forging new biomedical frontiers with FirePlex miRNA and immunoassays. From biotechnology to clinical care, FirePlex profiling technology provides the analytical power to ask new questions, drive new avenues of research and provide the answers that drive medicine forward.
The superior performance of FirePlex assays and their ability to push the bounds of biomedical research is reflected in the publication record and representation in the highest impact journals.
Find out how the FirePlex® particle technology works to allow multiplexed analysis from 5 to 400 miRNAs simultaneously in a single sample, or up to 70 protein analytes.
FirePlex immunoassays are new to the scene and are starting to emerge in high-impact publications as a powerful tool for analyte profiling. FirePlex multiplexing data is helping researchers reveal immune defense mechanisms against infectious diseases, as well as pathology behind immunological dysfunction.
2.1 Clinical-focused studies
Researchers are using FirePlex miRNA assays to define and utilize biomarkers across the medical landscape, from disease diagnosis to treatment selection and patient monitoring. By enabling these precision medicine approaches to clinical care, FirePlex is progressing medical capabilities against the most challenging diseases, from cancer to autoimmune disease and everything in between.
Our head-to-head comparison of the FirePlex Assay and qRT-PCR demonstrates that the FirePlex can eliminate intra-assay variables and improve reliability of miRNA quantification by directly targeting crude plasma and minimizing the complicated workflow.
Joerger M et al. (2014) Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 85(2): 306-313
Pregibon D and Plieskatt J. (2016) Detecting Circulating miRNA Biomarkers: Challenging Biobank Samples are Evaluated in Parasite-Induced Cholangiocarcinoma Study. Genetic Engineering and Biotechnology News 36(21)
Santos, MT et al. (2018) Molecular classification of thyroid nodules with indeterminate cytology: development and validation of a highly sensitive and specific new miRNA-based classifier test using fine-needle aspiration smear slides. Thyroid 0(JA)
2.1.2 Diabetes/Metabolic Disease
Listen to the webinar where Dr Elena Flowers of UCSF discusses how circulating microRNAs are emerging as useful biomarkers for evaluating changing environmental and behavioral risk factors associated with Type 2 Diabetes.
Joshi A, Goetzl L, Pinney S. (2018) Effect of Gestational Diabetes and Maternal Obesity on Fetal Programming—Are miRNAs Key Epigenetic Modifiers or Biomarkers of an Altered Intrauterine Milieu? Diabetes 67(Supplement 1)
2.1.3 Autoimmune Disease
Fernández-Ruiz JC et al. (2018) Analysis of miRNA expression in patients with rheumatoid arthritis during remission and relapse after a 5-year trial of tofacitinib treatment. Int Immunopharmacol. 63:35-42.
2.1.6 Cardiovascular Disease
Shah R et al. (2017) Small RNA-seq during acute maximal exercise reveal RNAs involved in vascular inflammation and cardiometabolic health: brief report. Integrative Cardiovascular Physiology and Pathophysiology 313(6): H1162-H1167
Glineur SF et al. (2016) Paving the Route to Plasma miR-208a-3p as an Acute Cardiac Injury Biomarker: Preclinical Rat Data Supports Its Use in Drug Safety Assessment. Toxicological Sciences 149 (1): 89–97
Glineur SF, et al. (2018) Assessment of a Urinary Kidney MicroRNA Panel as Potential Nephron Segment-Specific Biomarkers of Subacute Renal Toxicity in Preclinical Rat Models. Toxicological Sciences, kfy213
2.2 Molecular publications
Researchers are using FirePlex miRNA profiling technology to discover new molecular and genetic mechanisms of biology. By providing the tools to expose and examine these new mechanisms in model organisms, FirePlex is helping to open new doors of exploration that could lead to future medical and biotechnology advances.
Ren V, Ambros VR (2015). Caenorhabditis elegans microRNAs of the let-7 family act in innate immune response circuits and confer robust developmental timing against pathogen stress. Proc Natl Acad Sci USA 5;112(18).
Zinovyeva AY, Bouasker S, Simard MJ, Hammell CM, Ambros V (2014). Mutations in conserved residues of the C. elegans microRNA Argonaute ALG-1 identify separable functions in ALG-1 miRISC loading and target repression. PLoS Genet. 23, 10(4): e1004286.
Zinovyeva AY, et al. (2015) Caenorhabditis elegans ALG-1 antimorphic mutations uncover functions for Argonaute in microRNA guide strand selection and passenger strand disposal. PNAS 112 (38) E5271-E5280
Cave M et al. (2018) Mo1431 - Liquid Liver Biopsy is Consistent with Steatohepatitis in a Residential Cohort Suspected Toxicant Associated Steatohepatitis Related to Polychlorinated Biphenyl Exposures. AASLD Abstracts Gastroenterology 154(6) Supplement 1: S-1204
Elias KM et al. (2015) A prospective phase 0 study on the effects of anesthetic selection on serum miRNA profiles during primary cytoreductive surgery for suspected ovarian cancer. Gynecologic Oncology 137 (Supplement 1):137
Elias KM, Frendl G. (2017) Erasmos: Effects of regional analgesia on serum microRNA after oncologic surgery. Clinical Nutrition ESPEN 19: 76 OR07
Emily J, Arentson-Lantz EJ, Lamon S, Fry C, English K, Paddon-Jones D. (2017) Expression of skeletal muscle miRNA are unaltered during 14 days of bed rest but decrease following 7 days of reloading in middle-aged adults. FACEB Journal 31 (Supplement 1) Abstract Number:721.1
Hamed A, Brown MS, Szabela M, Slim J. (2018) Mo1428 - Regression of Liver Fibrosis after SVR from Direct-Acting Antivirals (DAAS) in Hepatitis C HIV Co-Infected Patients. Gastroenterology: AASLD Abstracts 154(6) Supplement 1: S-1203-S-1204
Minsart C et al. (2018) Mo1430 - Hepatocyte Release of HMGB1 During Acetaminophen-Induced Liver Injury and Deleterious Feed-Forward Process: Implication of Necroptosis Through TRIF/RIPK3 Axis. AASLD Abstracts Gastroenterology 154(6) Supplement 1:S-1204
Sastry A et al. (2017) The impact of goal directed intraoperative fluid administration during pancreaticoduodenectomy on pancreatic leaks and delayed gastric emptying. Hepato-Pancreato-Billiary Journal of Clinical Nutrition ESPEN 19, Supplement 1: S27
The FirePlex particle technology employs encoded hydrogel particles to provide the highest performance in multiplex biomarker detection. Read more about how this technology works, and how it has transformed miRNA and protein profiling capabilities.
The innovative FirePlex particle technology was conceptualized and created by Dr. Daniel Pregibon. The platform emerged from Pregibon’s PhD thesis at MIT, where he combined photolithography, used to build computer chips, with modern microfluidics techniques to generate customizable microgel particles for biological applications. The ground-breaking new technology promised to revolutionize personalized medicine with fast, easy and affordable biomarker testing; the seminal work was published in the journal Science.
While at MIT, the project was supported by multiple industry partners, as well as MIT’s Deshpande Center for Technological Innovation. Building off the academic success of the platform, Pregibon aimed to commercialize the technology by co-founding Firefly BioWorks, Inc., where he served as President and Chief Technology Officer. The company was awarded multiple grants from the National Cancer Institute and National Institute of Allergies and Infectious Disease at NIH, as well as Massachusetts Life Sciences Center, with a focus on early disease detection. With support from these grants and angel investment, Firefly BioWorks developed and commercialized the first assay capable of detecting circulating miRNA biomarkers directly from crude sample digests.
In 2015, Abcam acquired Firefly Bioworks to extend breadth of content offered on the platform, creating the FirePlex product line. Pregibon continues to impart his expertise, advancing the capabilities and impact of his revolutionary platform as General Manager of Platform Innovation at Abcam.
Helgeson ME, Chapin S, Doyle P. (2011) Hydrogel microparticles from lithographic processes: Novel materials for fundamental and applied colloid science. Curr Opin Colloid Interface Sci. 16(2): 106-7.
Markowska A. (2017) A novel method for the isolation of extracellular vesicles and RNA from urine. Journal of Circulating Biomarkers 6
See what people are saying about FirePlex:
Kilic T, Erdem A, Ozsoz M, Carrara S. (2018) microRNA biosensors: Opportunities and challenges among conventional and commercially available techniques. Current Opinion in Colloid & Interface Science 16(2):106-117
**Note- FirePlex technology was acquired by Abcam in 2015 from Firefly Bioworks. Publications prior to this date refer to the previous proprietary name, “Firefly Bioworks.”
Abcam’s FirePlex team develops, optimizes and validates FirePlex products through rigorous scientific studies to ensure the highest-performance capabilities. With an open approach to research and development, we share our data and seek input from colleagues and customers alike to guide the best product design. Our team members are active members of the research community, presenting their work at scientific conferences, research institutes and other venues for scientific review and feedback. We have recently presented posters and seminars at:
American Association of Cancer Research Annual Meeting
Heinrich B, Doran G, Atabakhsh E, Rafferty C, Pregibon D. (2017) High-throughput, purification-free, multiplexed profiling of circulating miRNA for discovery, validation, and diagnostics. Poster, AACR meeting 2017.
Tackett M, Kelley K, Doran G, Diwan I, Tejada G, Rafferty C, Atabakhsh E, Pregibon D. (2016) Multiplex profiling of circulating miRNAs for biomarker discovery and verification using the FirePlex platform. Poster, AACR meeting 2016.
Society for Laboratory Automation and Screening Annual Meeting
See Dr. Pregibon’s presentation for LabTube at SLAS 2018
Perea A, Heinrich B, Austin W, Rafferty C, Camilleri M, To L, Atabakhsh E, Pregibon D. (2018) Introducing FirePlex-HT: High-throughput, multiplex immunoassays using FirePlex particle technology. Poster
FirePlex® is a registered trademark in the United States and is an unregistered trademark elsewhere.
FirePlex immunoassays guide
FirePlex miRNA assay guide